Nuvation Bio Inc (NUVB) Stock Price, Quote & News

Company Profile

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; a...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 208 6102

Website: www.nuvationbio.com

Address:

1500 Broadway, Suite 1401, New York, United States

JFais Nov. 16 at 10:22 PM

$NUVB- Fwiw, Grimthorn shared how she was able to get on top of safu data so soon "Here’s a useful tidbit that I use frequently for unique keywords. For example, example, I have a Google alert set up for “Safusidenib” https://support.google.com/websearch/answer/4815696?hl=en Nifty trick even less tech savvy folks like me can do going forward👍

0 · Reply

JFais Nov. 16 at 10:07 PM

Great discussion in Chat today, hat tip to Houbi for digging up the publication. Here's my/our devil's advocate on $NUVB safu data:

0 · Reply

HedgeAlerts Nov. 16 at 9:57 PM

Hedge Alert Live - Protect Your Portfolio Contract: $NUVB $2.50 Put · NOV 21, 2025 Exp Entry Price: $0.04 - $0.05 Exit Price Target: $0.09 Profit Margin: +113% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Bio_Invest101 Nov. 16 at 2:22 PM

$NUVB Stay focused and sectors rotations are real. Don’t let the daily fluctuations distract you. Do the basic DD and Fundamentals are very strong in NUVB by any standards in any market conditions. Strong hold! https://youtu.be/FAWn8kWlvws?si=sIEUXfpPfFLKTiLs

0 · Reply

MoneyGroupLLC Nov. 16 at 12:26 PM

Enter: $NUVB Calls Strike Price: $8 Expiry Date: DEC 19 2025 Buy in Price: $0.10 - $0.10 Sell Price: $0.15 Profit : +51% (Turn every $1 into $1.51) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

HedgeAlerts Nov. 15 at 9:59 PM

0 · Reply

MoneyGroupLLC Nov. 15 at 8:11 AM

0 · Reply

LiquidThetaOptions Nov. 15 at 6:47 AM

💎 LiquidTheta® Live Actionable Trade Asset: $NUVB Contracts: $NUVB January 15, 2027 $5 Calls Scale in: $2.14- $2.61 Scale out: $8.31-$14.25 Profit Potential : 89% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Doom_Gloom_AR Nov. 15 at 4:53 AM

$NUVB potential here to do 3b a year in sales, if they stack up patients by saving their lives. Mpfs is > 50 months and growing. Potential to turn a 3000 people a year condition into a 15,000 people a year condition. Feels good to invest in good drugs. Once nuvl data is out of the way Monday this should fly.

0 · Reply

Doc_G Nov. 15 at 2:23 AM

$NUVB Sold half for 100% gain, riding the rest of the way with house money 😎

1 · Reply

Nuvation Bio: Ibtrozi's Rollout So Far Confirms Bullish Case

Nov 3, 2025, 9:46 PM EST - 13 days ago

Nuvation Bio Inc. (NUVB) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 4:05 PM EST - 13 days ago

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 30, 2025, 4:05 PM EDT - 17 days ago

Nuvation Bio to Participate in Upcoming Investor Conferences

Oct 23, 2025, 7:30 AM EDT - 24 days ago

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

Oct 20, 2025, 4:05 PM EDT - 27 days ago

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

Sep 30, 2025, 7:30 AM EDT - 6 weeks ago

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

Sep 29, 2025, 1:15 PM EDT - 6 weeks ago

3 Of My Favorite Biotech Stocks Under $10

DVAX FOLD MRNA PFE

Sep 19, 2025, 7:30 AM EDT - 2 months ago

Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Sep 15, 2025, 12:27 PM EDT - 2 months ago

Nuvation Bio: A Rare Gem In The Risky Biotech Space

Sep 7, 2025, 6:00 AM EDT - 2 months ago

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

Sep 5, 2025, 10:39 AM EDT - 2 months ago

Top 2 Health Care Stocks That May Plunge This Month

ESPR

Aug 28, 2025, 12:16 PM EDT - 2 months ago

Nuvation Bio: What To Expect From IBTROZI Launch?

Aug 7, 2025, 7:30 AM EDT - 3 months ago

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 8:00 AM EDT - 3 months ago

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Jul 24, 2025, 4:05 PM EDT - 4 months ago

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Jun 24, 2025, 7:00 AM EDT - 5 months ago

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

Jun 16, 2025, 7:30 AM EDT - 5 months ago

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.

Jun 11, 2025, 1:45 PM EDT - 5 months ago

US FDA approves Nuvation Bio's lung cancer therapy

Jun 11, 2025, 1:20 PM EDT - 5 months ago

U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

May 21, 2025, 4:05 PM EDT - 6 months ago

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

May 13, 2025, 4:05 PM EDT - 6 months ago

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025

May 11, 2025, 10:05 PM EDT - 6 months ago

Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 6 months ago

Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 9:07 AM EDT - 6 months ago

Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes

May 1, 2025, 4:05 PM EDT - 7 months ago

Nuvation Bio to Present at The Citizens Life Sciences Conference

Apr 22, 2025, 4:05 PM EDT - 7 months ago

Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

Apr 2, 2025, 8:00 AM EDT - 8 months ago

Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

Mar 25, 2025, 4:45 PM EDT - 8 months ago

Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

Mar 25, 2025, 8:00 AM EDT - 8 months ago

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

Mar 6, 2025, 4:30 PM EST - 9 months ago

Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 8:35 AM EST - 9 months ago

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

Feb 24, 2025, 8:00 AM EST - 9 months ago

Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 1:49 PM EST - 9 months ago

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm

Feb 13, 2025, 5:09 PM EST - 9 months ago

Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst

Feb 3, 2025, 8:00 AM EST - 10 months ago

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

Jan 6, 2025, 4:05 PM EST - 11 months ago

Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:00 AM EST - 11 months ago

Nuvation Bio Receives Approval from China's National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Jan 2, 2025, 7:00 PM EST - 11 months ago

Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration

Dec 23, 2024, 8:00 AM EST - 11 months ago

U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio's New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer

Dec 20, 2024, 7:10 AM EST - 11 months ago

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Nov 26, 2024, 8:00 AM EST - 1 year ago

Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 12, 2024, 4:05 PM EST - 1 year ago

Nuvation Bio to Present at the Jefferies London Healthcare Conference

Nov 11, 2024, 6:18 AM EST - 1 year ago

Top 4 Health Care Stocks That May Plunge This Quarter

AIRS PODD QDEL

Nov 6, 2024, 4:05 PM EST - 1 year ago

Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 7, 2024, 4:05 PM EDT - 1 year ago

Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer

Sep 14, 2024, 3:05 AM EDT - 1 year ago

Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Nuvation Bio to Present at the Cantor Global Healthcare Conference

Aug 8, 2024, 3:51 PM EDT - 1 year ago

Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

JFais Nov. 16 at 10:22 PM

0 · Reply

JFais Nov. 16 at 10:07 PM

Great discussion in Chat today, hat tip to Houbi for digging up the publication. Here's my/our devil's advocate on $NUVB safu data:

0 · Reply

HedgeAlerts Nov. 16 at 9:57 PM

0 · Reply

Bio_Invest101 Nov. 16 at 2:22 PM

0 · Reply

MoneyGroupLLC Nov. 16 at 12:26 PM

0 · Reply

HedgeAlerts Nov. 15 at 9:59 PM

0 · Reply

MoneyGroupLLC Nov. 15 at 8:11 AM

0 · Reply

LiquidThetaOptions Nov. 15 at 6:47 AM

0 · Reply

Doom_Gloom_AR Nov. 15 at 4:53 AM

0 · Reply

Doc_G Nov. 15 at 2:23 AM

$NUVB Sold half for 100% gain, riding the rest of the way with house money 😎

1 · Reply

Bio_Invest101 Nov. 15 at 12:20 AM

$NUVB Get to Know the new boss at CDER and Ibtrozi was FULL approval based on Ph2 data under his leadership in Oncology Center of Excellence (OCE) Safusidenib for 3-4 high grade ph3 could get green-lighted on AA pathway https://x.com/therealdansfera/status/1989381080768823753?s=46&t=0dxFfv8Iw4yOBhPO0oZagA

0 · Reply

Bio_Invest101 Nov. 14 at 11:21 PM

$NUVB Brand new buyer On November 14, 2025 - Woodline Partners LP filed a 13F-HR form disclosing ownership of 955,414 shares of Nuvation Bio Inc. (US:NUVB) valued at $3,535,032 USD as of September 30, 2025. The current value of the position is $4,480,892 USD. On November 14, 2025 - Tanaka Capital Management Inc filed a 13F-HR form disclosing ownership of 685,105 shares of Nuvation Bio Inc. (US:NUVB) valued at $2,534,888 USD as of September 30, 2025.

0 · Reply

Bio_Invest101 Nov. 14 at 11:16 PM

$NUVB Palo Alto Investors LP reports 32.08% increase in ownership of NUVB / Nuvation Bio Inc. On November 14, 2025 - Palo Alto Investors LP filed a 13F-HR form disclosing ownership of 1,020,547 shares of Nuvation Bio Inc. (US:NUVB) valued at $3,776,024 USD as of September 30, 2025. The entity filed a previous 13F-HR on August 14, 2025 disclosing 772,652 shares of Nuvation Bio Inc.. This represents a change in shares of 32.08% during the quarter.

0 · Reply

Bio_Invest101 Nov. 14 at 9:56 PM

$NUVB Tang Capital Management Llc reports 7.69% increase in ownership of NUVB / Nuvation Bio Inc. On November 14, 2025 - Tang Capital Management Llc filed a 13F-HR form disclosing ownership of 4,200,000 shares of Nuvation Bio Inc. (US:NUVB) valued at $15,540,000 USD as of September 30, 2025. The entity filed a previous 13F-HR on August 14, 2025 disclosing 3,900,000 shares of Nuvation Bio Inc.. This represents a change in shares of 7.69% during the quarter. The current value of the position is $19,698,000 USD.

1 · Reply

ak123456790 Nov. 14 at 7:03 PM

$NUVB Funds want to get in now that is cheap that is why you see the MM trying to shake retail constantly! Everyone knows that Hung is going to sell the company for 10b+… My estimation is between 14-17b until 2029…

0 · Reply

EndBas Nov. 14 at 6:03 PM

$NUVB one more shaky week next week. Then it will go $6+

0 · Reply

Bio_Invest101 Nov. 14 at 5:47 PM

$NUVB Huge volumes to 7 Million shares in first 2 hours Do you guys notice that there $NUVB SP moving down trends in 2-3 days we bounced harder in 1day to reach new highs? That’s standard higher lows and higher highs uptrend momentum in plays. Don’t be fooled by bears and shorts. 12 Million SI reduction is a good start. The longer the shorts hanging around the worse results for them. Fact is In next 1-3 Quarters near term NUVB has no bad catalyst in play. As for the very hot Biotrch/healthcare sector in M&A activities, it all pointing to a good sector recovery even I don’t believe Dr Hubg is interested in deal making at current stage but he can’t/won’t stop BP reaching out to him. MRSN yesterday and CDTD today are deals offered both over 100-200% premium and both have no, zero revenue.

1 · Reply

HedgeAlerts Nov. 14 at 5:41 PM

Hedge Alert Live - Protect Your Portfolio Contract: $NUVB $5.00 Put · NOV 21, 2025 Exp Entry Price: $0.10 - $0.60 Exit Price Target: $0.16 Profit Margin: +59% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Frida_m Nov. 14 at 5:22 PM

$NUVB holding full position Has not sold a share

1 · Reply

njbugatti Nov. 14 at 5:21 PM

$NUVB Cover charge to get in da Club is increasing to $5, $6, $7, etc. Soon the shorts aren't going to be hanging in da Club! Cover mfers!!!

0 · Reply

Bio_Invest101 Nov. 14 at 5:19 PM

$NUVB XBI just broke up 2-yrs highs again repeatedly and only 3 points more or less for 3 yrs high back in 2022 ( yes NUVB stock is not included in XBI yet but IWM) And IWM just broken up 5 yrs highs IMO sector rotations towards biotech biology and healthcare is for real. Better time ahead.

1 · Reply

44_BullDog Nov. 14 at 5:15 PM

$NUVB happy friday nuvation gang

1 · Reply

Market Cap	1.67B
Revenue (ttm)	7.87M
Net Income (ttm)	-567.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,216.52%
Debt to Equity Ratio	0.16

Volume	11,448,400
Avg Vol	7,902,882
Day's Range	N/A - N/A
Shares Out	342.83M
Stochastic %K	66%
Beta	1.50
Analysts	Strong Sell
Price Target	$8.83